“This CHMP recommendation marks a breakthrough in the treatment of triple-negative breast cancer, an aggressive type of breast cancer with high unmet medical need,” said Sandra Horning, MD,
The post CHMP recommends EU approval of Roche’s Tecentriq plus Abraxane for metastatic TNBC appeared first on Pharmaceutical Business review.